C Lerche-Langrand1, H J Toutain. 1. Drug Safety Evaluation, Aventis Pharma SA, 13 quai Jules Guesde, 94403, Vitry-sur-Seine, France. carole.langrand@aventis.com
Authors: Inge A M de Graaf; Peter Olinga; Marina H de Jager; Marjolijn T Merema; Ruben de Kanter; Esther G van de Kerkhof; Geny M M Groothuis Journal: Nat Protoc Date: 2010-08-19 Impact factor: 13.491
Authors: Martina Zimmermann; Johanna Lampe; Sebastian Lange; Irina Smirnow; Alfred Königsrainer; Claus Hann-von-Weyhern; Falko Fend; Michael Gregor; Michael Bitzer; Ulrich M Lauer Journal: Cytotechnology Date: 2009-12-20 Impact factor: 2.058
Authors: Nelly Aranibar; Michael Borys; Nancy A Mackin; Van Ly; Nicholas Abu-Absi; Susan Abu-Absi; Matthias Niemitz; Bernhard Schilling; Zheng Jian Li; Barry Brock; Reb J Russell; Adrienne Tymiak; Michael D Reily Journal: J Biomol NMR Date: 2011-03-04 Impact factor: 2.835
Authors: Anne Vittorelli; Catherine Gauthier; Christian Michoudet; Guy Martin; Gabriel Baverel Journal: Biochem J Date: 2005-05-01 Impact factor: 3.857